Ligand Pharmaceuticals completed the acquisition of Novan for $12.2m.

Ligand, a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines, completed the acquisition of Novan, a pharmaceutical company, for $12.2m. “We remain confident in the potential of berdazimer gel to be approved, and become an important treatment for molluscum contagiosum. There are currently no FDA-approved prescription drug treatment options for this commonly acquired, highly contagious viral skin disease, and, if approved by the FDA, berdazimer gel would be the first self-application topical treatment for this indication.” Matt Korenberg, Ligand President and COO.